Inhibition of TACE or amphiregulin for the Modulation of EGF Receptor Signal Transactivation

A method of making a pharmaceutical composition for prevention and or treatment of a disorder which is caused by or associated with a transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor mediated signal transduction in a cell comprising combining a therapeutically effective dose of an inhibitor that specifically inhibits the activity of amphiregulin and optionally TACE/ADAM17 with pharmaceutically acceptable carriers, diluents, and/or adjuvants.

A method for the prevention and or treatment of a disorder which is caused by or associated with a transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor mediated signal transduction comprising administering a subject in need thereof an effective amount of a specific inhibitor of amphiregulin and optionally a specific inhibitor of TACE/ADAM17.

A method for identifying modulators of receptor tyrosine kinase transactivation by G protein or G protein-coupled receptor mediated signal transduction, comprising determining if a test compound is capable of specifically inhibiting the activity of amphiregulin and optionally the activity of TACE/ADAM17.